AGP Executive Report

Vagus Nerve Breakthrough: Northwell/Feinstein researchers released the first comprehensive 3D human vagus nerve map, built from 60 nerves across 30 donors, aiming to speed bioelectronic and neuromodulation research. FDA Trial Reform: FDA’s Project Trialblazer is designed to streamline early clinical trials and cut months from timelines, as sponsors increasingly move studies abroad. Pharma Legal Shock: Johnson & Johnson offered $5.5bn to settle U.S. talc lawsuits tied to ovarian cancer claims, seeking to end 15 years of litigation. Cholesterol Update: The FDA approved Lipfendra, a new daily pill that cut cholesterol by 50%–60% in trials, with a Spokane cardiologist saying it could become routine for many patients. Hepatitis Strategy: A new push argues viral hepatitis elimination needs a broader approach beyond hepatitis B and C, including A, D and E. Care Access & Systems: Interoperability gains are improving EHR data exchange, but the next hurdle is turning connected data into real patient understanding for better decisions. Public Health Watch: India approved its first dengue vaccine (Qdenga) and reported 21.4% of teenagers at moderate-to-high substance-use risk. Clinical Trials & Safety: FDA issued new psychedelic drug guidance, signaling a maturing industry but highlighting the hard work ahead. GLP-1 Side Effect: A BMJ study found a small increased risk of non-scarring hair loss with GLP-1 drugs. Healthcare Workforce: New York proposes easing CNA training hours to help address nursing aide shortages.

FDA & ADHD Care: Otsuka’s Simtriyo (centanafadine) won FDA approval as the first triple reuptake inhibitor for ADHD in adults and kids age 6+, with availability later this year after DEA scheduling. Big Pharma Dealmaking: Argenx agreed to buy Forte Biosciences for about $2.2B, expanding its autoimmune playbook after Forte’s early vitiligo and celiac data. Cancer Screening Upgrade: FDA cleared Freenome’s SimpleScreen CRC, a blood test for colorectal cancer screening in average-risk adults 45+, aiming to boost participation beyond stool-based options. Bladder Cancer Precision: A panel stressed why accurate CIS diagnosis matters, since it changes prognosis and can open doors to specific intravesical therapies and trial eligibility. Healthcare Policy Pressure: Medicare’s proposed 2027 physician cut is 1.68%, but the bigger concern is payment rule changes that could reduce reimbursement more broadly. Public Health Watch: The cyclospora outbreak continues to spread, with Minnesota guidance urging people not to abandon fresh produce—just follow food-safety steps and monitor recalls. Care Access & Workforce: The end of Haiti TPS threatens staffing and services in long-term care, including nursing assistants and caregivers. Tech in Medicine: A wearable patch for continuous Parkinson’s levodopa monitoring in sweat points toward more responsive, closed-loop dosing.

Healthcare Investment: Aster DM Quality Care will invest ₹1,315 crore to expand and upgrade Karnataka’s hospital network, including new 550-bed and 460-bed facilities in Bengaluru and a 350-bed expansion at Aster CMI Hospital. Digital Health & AI: China’s hospital administration leaders say high-quality, governed health data is the key to making AI useful in real clinical settings, pushing for standardization, security, and better data ecosystems. FDA & Ophthalmology: Outlook Therapeutics finally secured FDA approval for its wet AMD therapy after multiple FDA setbacks, marking a long-awaited US milestone for a bevacizumab-based formulation. Public Health Alerts: The US reported more than 2,000 measles cases in 2026 as vaccination rates fall, while UK travel guidance warns Cyclospora is spreading via contaminated produce and summer travel. Autoimmune M&A: argenx agreed to buy Forte Biosciences for up to $2.2 billion to strengthen its autoimmune pipeline, including Forte’s FB102 in vitiligo. End-of-Life Care Policy: Haryana began implementing Supreme Court right-to-die with dignity guidelines, requiring legally defined protocols and medical boards for withdrawal of life support. Cancer Screening Innovation: India’s Dognosis is developing a dog-smell breath test for early blood cancer risk screening, aiming for a 2027 launch if clinical studies succeed.

Biopharma Dealmaking: Samsung Biologics agreed to buy PolyPeptide Group, expanding peptide manufacturing capacity and adding GLP-1-related services. Public Health Watch: A cyclospora outbreak linked to lettuce has spread across the U.S., with nearly 2,000 cases reported since May 1 and ongoing FDA/CDC investigation. HIV Prevention Funding: At AIDS 2026, Zambia’s officials say U.S. prevention cuts are forcing rationing of lenacapavir PrEP doses, even as treatment supplies remain steadier. HIV Prevention Resilience: Researchers and advocates at the conference warn that weakened community delivery systems could blunt even strong HIV prevention science. Healthcare Policy: Delaware signed bills to lower costs, boost primary care spending, expand hospital charity care, and protect hospitals from certain private equity ownership. Clinical Cell Therapy: A CAR T-cell toxicity session highlighted how CAR expansion can predict toxicity risk differently by product, shaping earlier intervention strategies. Care Delivery & Billing: A study found pharmacies most likely to bill medical claims were those already offering cash-pay clinical services and using credentialed pharmacists. Mental Health & Youth: Research links total abortion bans to higher suicidal thoughts among female teens, raising concerns about policy-driven mental health impacts. Tech for Access: An open-source, portable low-field MRI project is gaining attention for potentially making scanning far cheaper than standard machines.

US Tariffs on Generics: Trump’s proposed phased 0%→100%→200% tariff plan for imported generic medicines is raising alarms for India’s pharma export model and pushing calls for diversification, innovation, and resilient supply chains. Public Health Crisis: Congo’s Ebola outbreak has surged past 3,000 confirmed cases with 1,354 deaths, and experts warn conflict is hampering response as researchers race for a Bundibugyo vaccine. Dermatology Breakthrough: A study suggests pigment cells in vitiligo lesions may be reactivated, pointing to new approaches beyond current inflammation-focused treatments. Clinical Trial Watch: The SASAN-SPARING trial explores bladder preservation after neoadjuvant cisplatin in muscle-invasive bladder cancer, aiming to reduce quality-of-life tradeoffs without sacrificing outcomes. Healthcare Tech & Trust: Samsung is going all-in on AI health features, but questions remain about whether users trust how their data is used. Care Access & Policy: Massachusetts is advancing a bill to boost primary care spending share, while critics warn about costs and implementation. Mental Health & Stigma: Research finds self-esteem doesn’t protect commercial sex workers from stigma-related mental health harm. Global Health Systems: Yucatán’s maternal-child hospital transfer to IMSS Ordinario sparks backlash over access for uninsured families.

Trade Shock for Pharma: Trump’s three-phase tariff plan on imported generic medicines—0% until Aug. 1, 2028, then 100% for a year, and 200% after—puts India’s “pharmacy of the world” supply chain under pressure, with US patients and healthcare budgets at stake. Public Health Outbreak Watch: The FDA and CDC widened a cyclosporiasis investigation tied to shredded iceberg lettuce, now spanning nine states and nearly 2,000 reported infections. Hospital Price Transparency: The US warned hundreds of hospitals on price-disclosure compliance; Tennessee Valley facilities were named, with at least one citing a website “glitch.” Clinical Supply Chain Strain: A breast biopsy needle shortage linked to a recall is forcing clinicians to rethink reliance on single technologies. Neurology & Dementia Care: FDA accepted a biologics license application for DYNE-251 in Duchenne; the Alzheimer’s Association launched PROTECT-Cog, while a hospice-eligible dementia agitation trial reported positive results for a THC/CBD combo. Infectious Disease Reminder: A new look at histoplasmosis argues it’s more widespread than “rare zebra” training suggests. Maternal Health Access: A US report highlights how rural maternity networks used telehealth, monitoring, navigation, and doulas to expand care.

Measles Alert: US CDC reports 2,318 measles cases in 2026—surpassing last year’s total and the highest level since 1991—prompting renewed focus on MMR protection for travelers and World Cup returnees. UK Workforce & Training: The Royal College of Physicians says doctor burnout remains widespread despite “small green shoots” in the GMC training survey, and calls for a workforce retention strategy plus safer, more inclusive training environments. NHS Policy Push: RCP also urges the new UK government to prioritize health inequalities, prevention, social care reform, and long-term NHS workforce planning. Healthcare Access & Capacity (India): Aster DM Quality Care plans Rs 1,315 crore investment in Karnataka to expand hospitals and beds after its merger-driven network buildout. Drug Development: Celcuity’s REVTORPYK (gedatolisib) gains FDA approval for HR+/HER2−, PIK3CA wild-type breast cancer in combination regimens, with further sNDA plans for PIK3CA-mutant disease. Clinical Safety Signal: The TREASURE trial finds adding consolidative thoracic radiotherapy to atezolizumab increases severe/fatal toxicity without survival benefit in extensive-stage small cell lung cancer. Public Health Food Safety: FDA recalls 1.59 million dozen eggs over possible salmonella contamination, with no illnesses reported yet.

Workplace Safety: OhioHealth Van Wert Hospital is rolling out weapons-free screening for visitors as healthcare violence rises, citing Bureau of Labor Statistics data and the high costs of aggression. Prostate Cancer Care: New CAPTAIN trial analysis reports MRI-guided TULSA preserved penile length at 1 month versus penile shrinkage after robotic prostatectomy, with longer-term cancer outcomes still pending. Cardio-Metabolic Guidelines: The AHA/ACC’s new CKM (cardiovascular-kidney-metabolic) guideline pushes earlier screening and coordinated prevention across heart, kidney, diabetes, and obesity. Skilled Nursing Finance: A $308M HUD-insured refinance and $70.8M bridge loan supported SNF ownership changes across Ohio and the Midwest. AI in Biotech: Biointron launched RushData to speed antibody discovery by combining rapid CHO expression with binding and early developability profiling in days. Public Health Outbreaks: Cyclospora cases tied to iceberg lettuce topped 4,000 as a second cluster emerged; U.S. measles cases hit a 35-year high. Mental Health Policy: Ireland banned electroshock treatment for minors, while U.S. HIPAA rule updates continue to stir compliance confusion. Cardiology Research: Cleveland Clinic links higher gut bacteria byproduct TMAO levels to increased atrial fibrillation risk. Healthcare Tech & Trials: Oxford began first human dosing of an experimental Ebola vaccine targeting the Bundibugyo strain.

Gut Health & Diet: Experts warn that eating biscuits with evening tea—especially those made with refined flour and added sugar—may worsen bloating, gas and acidity by disrupting gut bacteria and the intestinal lining, with added risk during monsoon season. STI Drug Update: A review highlights zoliflodacin as a new single-dose FDA-approved option for uncomplicated urogenital gonorrhea, aiming to help tackle rising multidrug-resistant cases. Weight-Loss Medication Watch: A doctor explains hair loss risk with GLP-1 weight-loss drugs, noting rapid weight loss itself can trigger a “famine” response. Healthcare Policy (US): CMS issued implementation guidance after a court injunction affecting 2027 marketplace notice and payment parameters, including steps to stop wrongly removing premium tax credits. India Health System Expansion: India says medical colleges and MBBS seats have more than doubled since 2014, alongside rural training and village adoption programs. Maternal Care Oversight (India): Andhra Pradesh’s NTR Vaidya Seva scheme now requires audits for every C-section to curb unnecessary procedures. Cybersecurity: US and partners updated an advisory on Iranian-linked attacks targeting internet-connected programmable logic controllers used in industrial and healthcare settings. AI in Radiology: CARPL.ai raised $10M to help providers adopt and monitor radiology AI across workflows, while an LLM study suggests automation of ultrasound report quality checks. New Cancer Data: Trials report dupilumab benefits in eosinophilic gastritis and new results across multiple oncology settings, including prostate and bladder cancer research. Public Health Alerts: India reports no nationwide anti-rabies vaccine shortage, while a chikungunya travel advisory urges mosquito precautions as cases rise.

Obesity Drug Push: Eli Lilly reported new Phase 3 results for retatrutide, aiming for FDA approval next year after TRIUMPH-2 and TRIUMPH-3 showed about 21%–23% average weight loss at 80 weeks in key patient groups. FDA & Diagnostics: The FDA selected Dexcom as the first participant in a digital health pilot (TEMPO), using real-world data from CGMs plus lifestyle inputs to support earlier prediabetes and Type 2 diabetes intervention. Cancer Care Advances: KEYNOTE-B15/EV-304 data in NEJM back perioperative enfortumab vedotin plus pembrolizumab for muscle-invasive bladder cancer, improving event-free survival, overall survival, and pathologic complete response. Oncology Regulation: FDA granted priority review to talazoparib plus enzalutamide for HRR gene-altered metastatic castration-sensitive prostate cancer. Clinical Workflow & Safety: Research warns medication alert systems are widely used but often underperform due to poor relevance and integration—calling for alert optimization. Public Health Communication: A cyclosporiasis outbreak story highlights how a false positive test can still leave consumers confused, underscoring the need for clearer guidance during fast-moving food safety investigations. Workforce & Policy: A proposed 2027 Medicare Physician Fee Schedule signals another pay cut, with quality program changes adding more administrative pressure for practices.

GLP-1 Coverage Pressure: CVS is adding Eli Lilly’s Zepbound back to its formulary and covering an oral GLP-1, highlighting how cardiometabolic promise is colliding with payer cost and coverage friction. Safety Watch: A new study links GLP-1s to higher risk of hair loss, with regulators receiving hundreds of reports tied to semaglutide and tirzepatide. Antibiotic Stewardship: A Lancet analysis finds nearly all countries overuse “watch” antibiotics, raising drug-resistance risk and underscoring the need for smarter national targets. NHS Access Update: With Fampyra patents now expired, England’s NICE is clearing generic fampridine for NHS use in eligible people with multiple sclerosis. Cancer & Drug Approvals: GSK’s Jideytro (zidesamtinib) wins FDA approval for ROS1-positive NSCLC after prior therapy, while Summit Therapeutics shares new ivonescimab Phase 3 data as regulators weigh a decision. Healthcare Policy & Costs: The AHA pushes back on U.S. price-transparency proposals for imaging, warning of heavy admin burdens—especially for small and rural hospitals. Industry & Supply Chain: Sotera Health sets its Q2 earnings date, while Envirotainer expands cold-chain capacity in Navi Mumbai to support pharma logistics.

Drug Safety & Recalls: Unique Pharmaceutical Laboratories voluntarily recalls four lots of cetirizine tablets after potential cross-contamination with ranitidine, warning of serious hypersensitivity and anaphylaxis risk for sensitive patients. Workforce Policy: The AAMC backs Senate HELP Committee action advancing the EMPOWER for Health Act and nursing workforce reauthorization to sustain HRSA training and access programs. Payer Access Rules: New survey data show Medicare Part D and commercial plans increasingly using step therapy, formulary exclusions, prior authorization, and biosimilar preference as IRA rules reshape benefit design. Ophthalmology Costs Beyond the Drug: Anti-VEGF retinal injections drive higher patient spending from travel and lost wages than the medication and visit costs combined. Oncology Trial Safety Signal: Atezolizumab plus consolidative thoracic radiotherapy in extensive-stage small cell lung cancer was stopped early after a rise in fatal adverse events. Pharma Manufacturing & Regulation: FDA launches a pilot to boost US manufacturing of animal drugs, aiming to strengthen domestic supply continuity. Biotech Funding: Crystalys Therapeutics raises $130M Series B to advance its gout drug dotinurad through late-stage testing. AI in Pharma Reality Check: Industry benchmarking finds AI use is uneven and mostly limited to documentation and compliance, with few fully embedded workflows. Generic Drug Tariffs: Trump announces phased zero-to-200% tariffs on imported generics starting after a reprieve, raising major supply-chain and pricing concerns.

Cell Therapy Deal: MaxCyte signed a technology license partnership with Genentech to use its ExPERT GTx platform across cell-engineering, analytics, and cGMP workflows. Bradykinin Angioedema Research: Pharvaris published a comprehensive review in Clinical Reviews in Allergy & Immunology backing bradykinin B2 receptor antagonism as a validated approach for bradykinin-mediated angioedema. AI in Pharma Adoption: A new report warns pharma’s AI spend is outpacing real use at key discovery steps, blaming fragmented data readiness and a “trust gap” between models and bench scientists. GLP-1 Coverage Pressure: Coverage gaps for employer benefits and Medicare are still shaping access to GLP-1s, with early Medicare pilot signals showing many older patients choosing injectables. Childhood Obesity Evidence: A meta-analysis suggests GLP-1 weight-loss injections may help some children with obesity, but only under specialist supervision due to side effects and unknown long-term safety. Clinical Trials Reform: FDA’s Project TrialBlazer aims to speed early trial timelines and bring more studies back to the U.S. Stroke Rehab Tech: Marengo Asia Hospitals launched rTMS to support stroke rehabilitation and neuroplasticity. Lung Cancer Screening Gap: A study finds only ~13% of lung cancer patients met low-dose CT screening criteria, highlighting eligibility and uptake barriers. Policy & Payments: A court ruled manufacturers can’t impose certain 340B rebate models without HHS approval; AHA also weighed in on Medicaid supplemental payments, provider tax rules, and price transparency bills. Tariffs Shake Pharma: Trump’s phased up-to-200% tariff plan for imported generic drugs is roiling markets and raising concerns about feasibility, supply-chain timing, and costs. PE-RADS Standardization: A new PE-RADS v2026 reporting framework is set to standardize CT/MR pulmonary embolism imaging communication across care teams. Neuro Workforce Concern (India): Experts warn rising neurological disorders are colliding with a shortage of neurologists, delaying diagnosis and treatment.

Texas Crackdown on Birth Tourism: Texas Gov. Greg Abbott signed an executive order directing multiple state health and licensing agencies to investigate alleged “birth tourism” schemes and pursue enforcement against providers who advertise, solicit, assist, or facilitate them, framing the activity as fraud and warning that penalties could include license action. Payment for Clinical AI: A new report from the Peterson Health Technology Institute says today’s common reimbursement models don’t properly pay for providers’ growing use of clinical AI, especially more autonomous tools, which could slow adoption. Cyclospora Update: Health officials say the U.S. cyclosporiasis outbreak is “under control,” while Mexico casts doubt on a link to a Taylor Farms facility as investigators continue tracing the source. Diabetes Care Boost from CGM: A study in JAMA Network Open finds primary-care CGM prescriptions for insulin-treated adults meaningfully lower HbA1c and reduce acute care events over time. Oncology & Pharma Moves: Telix dosed the first patient in a phase 3 trial of a CAIX-targeting radiopharmaceutical for relapsed clear cell renal cell carcinoma, while Agios stops a sickle cell drug after phase 2 results didn’t differentiate enough. GLP-1 Legal Fight: Novo Nordisk sued Eli Lilly over “misleading” GLP-1 advertising comparisons, escalating the weight-loss drug rivalry. Clinical Safety & Workforce: Hazelden Betty Ford nurses begin a strike seeking a first contract, and separate reporting highlights how unmanaged clinician AI use raises HIPAA and cybersecurity risks.

GMP & Quality Ops: InstantGMP rolled out agentic AI inside its InstantGMP platform so manufacturers can ask natural-language questions and get cross-module answers on deviations, CAPAs, batch status, and inspection readiness in minutes. FDA & Patient Safety: GE HealthCare recalled certain Optima XR Mobile Digital-Ready radiographic systems after column replacement work may skip safety testing, risking arm drop and potential patient injury. Medicare Access Fight: A Senate vote blocked Democrats’ effort to end the Medicare AI prior authorization pilot (WISeR), keeping the program alive while opponents vow to continue. Public Health Targets: China released its 2026–30 health plan aiming to curb chronic disease and raise life expectancy to 80 by 2030, alongside stronger smoking-cessation goals and expanded fertility/childcare services. Long COVID Treatment Research: UK researchers launched a randomized platform trial testing rivaroxaban, colchicine, and antihistamine-loratidine for persistent post-acute COVID fatigue. Diagnostics & Care Delivery: Radiology Partners named Matt Peterson to lead clinical services, while a study warned many incidental breast masses on emergency chest CTs are missed, delaying cancer diagnosis. Identity Verification in Benefits: Medi Assist integrated Aadhaar Offline Verification into health benefits platforms to reduce paperwork and identity misuse risk. Dengue Vaccine Milestone (India): CDSCO approved Takeda’s Qdenga for ages 4–60, marking India’s first dengue vaccine authorization.

Biomanufacturing Flexibility: WuXi Biologics says it converted a batch pilot line to continuous processing at 100-L scale without building dedicated continuous equipment, using membrane chromatography to lower the usual capital barrier. Value-Based Care Economics: A new open-source playbook from Ten Ten Ten argues independent primary care practices are losing too much shared-savings value to intermediaries instead of reinvesting in care delivery. Controlled Substances Compliance: Guidance highlights that DEA registrations and controlled-substance inventory are the registrant’s legal responsibility—employment contracts can’t override federal rules during practice transitions. AI in Drug Discovery: Bristol Myers Squibb expands its Nvidia compute setup with a DGX SuperPOD to accelerate AI-driven hypothesis generation. Alzheimer’s Access Shift: FDA cleared a subcutaneous starting dose for lecanemab, enabling earlier at-home weekly self-injection for eligible patients. Cyclospora Response: FDA and CDC stress the investigation is ongoing after a false-positive test, while Mexico launches a preventive probe into the lettuce supply chain tied to the outbreak. Workforce Policy: Wisconsin approved an emergency rule allowing qualified RNs to teach clinical courses to ease nursing shortages. Vet Industry Leadership: NVA added two major healthcare leaders to its board, signaling continued expansion in animal health services.